Akari Therapeutics Plc (AKTX): Price and Financial Metrics


Akari Therapeutics Plc (AKTX): $0.25

-0.01 (-2.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AKTX Stock Price Chart Interactive Chart >

Price chart for AKTX

AKTX Price/Volume Stats

Current price $0.25 52-week high $1.61
Prev. close $0.26 52-week low $0.22
Day low $0.24 Volume 108,500
Day high $0.27 Avg. volume 131,551
50-day MA $0.40 Dividend yield N/A
200-day MA $0.69 Market Cap 18.65M

Akari Therapeutics Plc (AKTX) Company Bio


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company is based in London, United Kingdom.


AKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

AKTX Latest Social Stream


Loading social stream, please wait...

View Full AKTX Social Stream

Latest AKTX News From Around the Web

Below are the latest news stories about AKARI THERAPEUTICS PLC that investors may wish to consider to help them evaluate AKTX as an investment opportunity.

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the late-breaker presentation of a patient case study from the Phase 3 Part A clinical trial of nomacopan in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The case study, Clinical Response to Nomacopan in the Pediatric HSCT-TMA Setting,

Yahoo | February 21, 2023

Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024Composition of matter patent application filed on long-acting PAS-nomacopan versions, which, if granted, provides patent protection until 2042Pre-clinical development on long-acting PAS-nomacopan has successfully produced multiple new and promising versions that are fully active, show high expression levels and have significantly enlarged hydrodynamic radi

Yahoo | February 15, 2023

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults

Based on Type C guidance requested and received from the U.S. Food and Drug Administration (FDA), Akari announces it is moving forward into design and planning for pivotal Part B of the Phase 3 clinical trial of nomacopan for treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) in pediatric patients between 2 years and <18 years of ageAccording to FDA feedback, the PK/PD data from Part A of the clinical trial are consistent with predictions from

Yahoo | February 13, 2023

Akari Therapeutics to Present at Biotech Showcase™ 2023

NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari’s two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a nove

Yahoo | January 4, 2023

Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will participate in the investor-focused Cantor Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference taking place in Miami December 7-8, 2022. Akari President and CEO Rachelle Jacques will take part in an ophthalmology panel on December 8 a

Yahoo | December 1, 2022

Read More 'AKTX' Stories Here

AKTX Price Returns

1-mo -28.31%
3-mo -44.44%
6-mo -54.46%
1-year -79.45%
3-year -83.66%
5-year -86.63%
YTD -46.80%
2022 -68.67%
2021 -18.92%
2020 5.71%
2019 11.46%
2018 -63.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7651 seconds.